Clinical Focus

  • Anesthesiology
  • Residency

Boards, Advisory Committees, Professional Organizations

  • Chief Resident, Stanford University, Anesthesiology (2023 - 2024)
  • Member, California Society of Anesthesiologists (2021 - Present)
  • President of ASA Resident Component (2020-2022), President of ASA Med Student Component (2017-2019), American Society of Anesthesiologists (2016 - Present)
  • Member, Michigan Society of Anesthesiologists (2016 - 2020)

Professional Education

  • Residency, Stanford University, Anesthesiology
  • Internship, Kaiser Permanente San Francisco Medical Center, Preliminary Internal Medicine (2021)
  • MD, Oakland University William Beaumont School of Medicine (2020)
  • BS, Massachusetts Institute of Technology, Biological Engineering (2016)

All Publications

  • Development and Validation of an Efficient Pediatric Affect Scale Kennedy, K. M., Khoury, M., Kist, M., Wang, E., Rodriguez, S., Jackson, C., Yuan, J. C., Caruso, T. LIPPINCOTT WILLIAMS & WILKINS. 2021: 751-752
  • Unique considerations of virtual reality utilization for perioperative pediatric patients. Paediatric anaesthesia Yuan, J. C., Rodriguez, S., Caruso, T. J. 2021; 31 (3): 377–78

    View details for DOI 10.1111/pan.14108

    View details for PubMedID 33631038

  • Role of Gamma Knife Radiosurgery in Small Cell Lung Cancer: A Multi-Institutional Retrospective Study of the International Radiosurgery Research Foundation (IRRF) NEUROSURGERY Cifarelli, C. P., Vargo, J. A., Fang, W., Liscak, R., Guseynova, K., Warnick, R. E., Lee, C., Yang, H., Borghei-Razavi, H., Maiti, T., Siddiqui, Z. A., Yuan, J. C., Grills, I. S., Mathieu, D., Touchette, C. J., Cordeiro, D., Chiang, V., Hess, J., Tien, C. J., Faramand, A., Kano, H., Barnett, G. H., Sheehan, J. P., Lunsford, L. 2020; 87 (4): 664-671


    Despite a high incidence of brain metastases in patients with small-cell lung cancer (SCLC), limited data exist on the use of stereotactic radiosurgery (SRS), specifically Gamma Knife™ radiosurgery (Elekta AB), for SCLC brain metastases.To provide a detailed analysis of SCLC patients treated with SRS, focusing on local failure, distant brain failure, and overall survival (OS).A multi-institutional retrospective review was performed on 293 patients undergoing SRS for SCLC brain metastases at 10 medical centers from 1991 to 2017. Data collection was performed according to individual institutional review boards, and analyses were performed using binary logistic regression, Cox-proportional hazard models, Kaplan-Meier survival analysis, and competing risks analysis.Two hundred thirty-two (79%) patients received SRS as salvage following prior whole-brain irradiation (WBRT) or prophylactic cranial irradiation, with a median marginal dose of 18 Gy. At median follow-up after SRS of 6.4 and 18.0 mo for surviving patients, the 1-yr local failure, distant brain failure, and OS were 31%, 49%, and 28%. The interval between WBRT and SRS was predictive of improved OS for patients receiving SRS more than 1 yr after initial treatment (21%, <1 yr vs 36%, >1 yr, P = .01). On multivariate analysis, older age was the only significant predictor for OS (hazard ratio 1.63, 95% CI 1.16-2.29, P = .005).SRS plays an important role in the management of brain metastases from SCLC, especially in salvage therapy following WBRT. Ongoing prospective trials will better assess the value of radiosurgery in the primary management of SCLC brain metastases and potentially challenge the standard application of WBRT in SCLC patients.

    View details for DOI 10.1093/neuros/nyz428

    View details for Web of Science ID 000593121100030

    View details for PubMedID 31599324

    View details for PubMedCentralID PMC7780439

  • Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases The FIRE-SCLC Cohort Study JAMA ONCOLOGY Rusthoven, C. G., Yamamoto, M., Bernhardt, D., Smith, D. E., Gao, D., Serizawa, T., Yomo, S., Aiyama, H., Higuchi, Y., Shuto, T., Akabane, A., Sato, Y., Niranjan, A., Faramand, A. M., Lunsford, L., McInerney, J., Tuanquin, L. C., Zacharia, B. E., Chiang, V., Singh, C., Yu, J. B., Braunstein, S., Mathieu, D., Touchette, C. J., Lee, C., Yang, H., Aizer, A. A., Cagney, D. N., Chan, M. D., Kondziolka, D., Bernstein, K., Silverman, J. S., Grills, I. S., Siddiqui, Z. A., Yuan, J. C., Sheehan, J. P., Cordeiro, D., Nosaki, K., Seto, T., Deibert, C. P., Verma, V., Day, S., Halasz, L. M., Warnick, R. E., Trifiletti, D. M., Palmer, J. D., Attia, A., Li, B., Cifarelli, C. P., Brown, P. D., Vargo, J. A., Combs, S. E., Kessel, K. A., Rieken, S., Patel, S., Guckenberger, M., Andratschke, N., Kavanagh, B. D., Robin, T. P. 2020; 6 (7): 1028-1037


    Although stereotactic radiosurgery (SRS) is preferred for limited brain metastases from most histologies, whole-brain radiotherapy (WBRT) has remained the standard of care for patients with small cell lung cancer. Data on SRS are limited.To characterize and compare first-line SRS outcomes (without prior WBRT or prophylactic cranial irradiation) with those of first-line WBRT.FIRE-SCLC (First-line Radiosurgery for Small-Cell Lung Cancer) was a multicenter cohort study that analyzed SRS outcomes from 28 centers and a single-arm trial and compared these data with outcomes from a first-line WBRT cohort. Data were collected from October 26, 2017, to August 15, 2019, and analyzed from August 16, 2019, to November 6, 2019.SRS and WBRT for small cell lung cancer brain metastases.Overall survival, time to central nervous system progression (TTCP), and central nervous system (CNS) progression-free survival (PFS) after SRS were evaluated and compared with WBRT outcomes, with adjustment for performance status, number of brain metastases, synchronicity, age, sex, and treatment year in multivariable and propensity score-matched analyses.In total, 710 patients (median [interquartile range] age, 68.5 [62-74] years; 531 men [74.8%]) who received SRS between 1994 and 2018 were analyzed. The median overall survival was 8.5 months, the median TTCP was 8.1 months, and the median CNS PFS was 5.0 months. When stratified by the number of brain metastases treated, the median overall survival was 11.0 months (95% CI, 8.9-13.4) for 1 lesion, 8.7 months (95% CI, 7.7-10.4) for 2 to 4 lesions, 8.0 months (95% CI, 6.4-9.6) for 5 to 10 lesions, and 5.5 months (95% CI, 4.3-7.6) for 11 or more lesions. Competing risk estimates were 7.0% (95% CI, 4.9%-9.2%) for local failures at 12 months and 41.6% (95% CI, 37.6%-45.7%) for distant CNS failures at 12 months. Leptomeningeal progression (46 of 425 patients [10.8%] with available data) and neurological mortality (80 of 647 patients [12.4%] with available data) were uncommon. On propensity score-matched analyses comparing SRS with WBRT, WBRT was associated with improved TTCP (hazard ratio, 0.38; 95% CI, 0.26-0.55; P < .001), without an improvement in overall survival (median, 6.5 months [95% CI, 5.5-8.0] for SRS vs 5.2 months [95% CI, 4.4-6.7] for WBRT; P = .003) or CNS PFS (median, 4.0 months for SRS vs 3.8 months for WBRT; P = .79). Multivariable analyses comparing SRS and WBRT, including subset analyses controlling for extracranial metastases and extracranial disease control status, demonstrated similar results.Results of this study suggest that the primary trade-offs associated with SRS without WBRT, including a shorter TTCP without a decrease in overall survival, are similar to those observed in settings in which SRS is already established.

    View details for DOI 10.1001/jamaoncol.2020.1271

    View details for Web of Science ID 000552068600011

    View details for PubMedID 32496550

    View details for PubMedCentralID PMC7273318

  • Active Virtual Reality Improves Vascular Access Compliance in Anxious Children Yuan, J. C., Joseph, A., Rodriguez, S., Caruso, T. J. LIPPINCOTT WILLIAMS & WILKINS. 2018: 114–15
  • Rare Bilateral Variation of the Extensor Carpi Radialis Longus Muscle Yuan, J. C., Brisson, R. J., Barremkala, M., Venuti, J. M., Thompson, B. J. WILEY. 2017
  • Provider-controlled virtual reality experience may adjust for cognitive load during vascular access in pediatric patients. Canadian journal of anaesthesia = Journal canadien d'anesthesie Yuan, J. C., Rodriguez, S. n., Caruso, T. J., Tsui, J. H. 2017

    View details for PubMedID 28861855

  • LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer EMBO MOLECULAR MEDICINE Sas-Chen, A., Aure, M. R., Leibovich, L., Carvalho, S., Enuka, Y., Koerner, C., Polycarpou-Schwarz, M., Lavi, S., Nevo, N., Kuznetsov, Y., Yuan, J., Azuaje, F., Ulitsky, I., Diederichs, S., Wiemann, S., Yakhini, Z., Kristensen, V. N., Borresen-Dale, A., Yarden, Y., Oslo Breast Canc Res Consortium 2016; 8 (9): 1052-1064


    Long noncoding RNAs (lncRNAs) are emerging as regulators of gene expression in pathogenesis, including cancer. Recently, lncRNAs have been implicated in progression of specific subtypes of breast cancer. One aggressive, basal-like subtype associates with increased EGFR signaling, while another, the HER2-enriched subtype, engages a kin of EGFR Based on the premise that EGFR-regulated lncRNAs might control the aggressiveness of basal-like tumors, we identified multiple EGFR-inducible lncRNAs in basal-like normal cells and overlaid them with the transcriptomes of over 3,000 breast cancer patients. This led to the identification of 11 prognostic lncRNAs. Functional analyses of this group uncovered LINC01089 (here renamed LncRNA Inhibiting Metastasis; LIMT), a highly conserved lncRNA, which is depleted in basal-like and in HER2-positive tumors, and the low expression of which predicts poor patient prognosis. Interestingly, EGF rapidly downregulates LIMT expression by enhancing histone deacetylation at the respective promoter. We also find that LIMT inhibits extracellular matrix invasion of mammary cells in vitro and tumor metastasis in vivo In conclusion, lncRNAs dynamically regulated by growth factors might act as novel drivers of cancer progression and serve as prognostic biomarkers.

    View details for DOI 10.15252/emmm.201606198

    View details for Web of Science ID 000383634100006

    View details for PubMedID 27485121

    View details for PubMedCentralID PMC5009810